Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 4:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 1,069 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo (Cohort 3) Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple Dose Escalation Trial Of PF-04308515 In Healthy Volunteers

NCT01101932
View directory record Official record
Conditions
Healthy
Interventions
PF-04308515, Placebo, PF-04308515 Tablet
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 25, 2011 · Synced Oct 15, 2026, 4:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Live Recombinant Newcastle Disease Virus-vectored COVID-19 Vaccine Phase 1 Study.

NCT05181709
View directory record Official record
Conditions
SARS-CoV-2
Interventions
Sodium Chloride, NDV-HXP-S IN low dose, NDV-HXP-S IM low dose, NDV-HXP-S IN high dose, NDV-HXP-S IM high dose
Drug · Biological
Lead sponsor
Sean Liu
Other
Eligibility
18 Years to 59 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Oct 15, 2026, 4:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Learn How Different Amounts of the Study Medicine Called PF-06954522 Are Tolerated and Act in the Body in Healthy Adults

NCT06003777
View directory record Official record
Conditions
Healthy Participants
Interventions
PF-06954522, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Oct 15, 2026, 4:24 AM EDT
Terminated Phase 2Phase 3 Interventional

Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas

NCT05130866
View directory record Official record
Conditions
Neurofibromatosis Type 2
Interventions
REC-2282, Placebo
Drug
Lead sponsor
Recursion Pharmaceuticals Inc.
Industry
Eligibility
12 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
14
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Gainesville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 15, 2026, 4:24 AM EDT
Recruiting Phase 2 Interventional

Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH

NCT07335601
View directory record Official record
Conditions
MASH - Metabolic Dysfunction-Associated Steatohepatitis
Interventions
Resmetirom, Placebo
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
16
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 15, 2026, 4:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

This Study Will Investigate the Safety, Tolerability and Pharmacokinetic Profile of Repeat Oral Doses of GSK2140944 in Healthy Adult Subjects

NCT01706315
View directory record Official record
Conditions
Infections, Respiratory Tract
Interventions
GSK2140944, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 15, 2026, 4:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Multiple Doses of Lasmiditan in Healthy Participants

NCT03252015
View directory record Official record
Conditions
Healthy
Interventions
Probe Drug Cocktail, Lasmiditan, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jan 10, 2020 · Synced Oct 15, 2026, 4:24 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)

NCT04329923
View directory record Official record
Conditions
COVID-19
Interventions
Hydroxychloroquine Sulfate 400 mg twice a day, Hydroxychloroquine Sulfate 600 mg twice a day, Hydroxychloroquine Sulfate 600 mg once a day, Placebo oral tablet
Drug
Lead sponsor
Ravi Amaravadi, MD
Other
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Oct 15, 2026, 4:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AZD3366 in Healthy Subjects, Japanese and Chinese Subjects

NCT04588727
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
AZD3366, Placebo, Ticagrelor, acetylsalicylic acid (ASA)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Oct 15, 2026, 4:24 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity

NCT07575932
View directory record Official record
Conditions
Overweight, Obesity, Overweight and/or Obesity, Overweight or Obesity, Overnutrition, Nutrition Disorders, Nutritional and Metabolic Diseases, Body Weight
Interventions
PF-08653945, PF-08653944, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
940 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
53
States / cities
Sun City West, Arizona • Canoga Park, California • Fountain Valley, California + 45 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 15, 2026, 4:24 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria

NCT06069544
View directory record Official record
Conditions
Malaria
Interventions
BNT165c, BNT165d, Placebo
Biological · Other
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years to 55 Years
Enrollment
163 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
5
States / cities
Tempe, Arizona • Baltimore, Maryland • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 15, 2026, 4:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effects of GLA on Human Volunteers

NCT01397604
View directory record Official record
Conditions
Healthy Volunteers
Interventions
GLA-AF, GLA-SE, Squalene
Drug · Other
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 23, 2013 · Synced Oct 15, 2026, 4:24 AM EDT
Recruiting Phase 3 Interventional

A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With α- or β-Non-Transfusion-Dependent Thalassemia

NCT07517133
View directory record Official record
Conditions
Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia
Interventions
Mitapivat, Placebo Matching Mitapivat
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
1 Year to 17 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
5
States / cities
Palo Alto, California • Atlanta, Georgia • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 15, 2026, 4:24 AM EDT
Completed Phase 1 Interventional

A Study to Test How SB756050 Affects Subjects With Type 2 Diabetes Mellitus After 6 Days of Dosing.

NCT00733577
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
SB756050
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2017 · Synced Oct 15, 2026, 4:24 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia

NCT06712654
View directory record Official record
Conditions
Hyperphosphatemia, Chronic Kidney Disease Requiring Chronic Dialysis, End Stage Renal Disease on Dialysis
Interventions
AP306 75 mg BID, AP306 125 mg BID, AP306 150 mg BID, AP306 75 mg TID, AP306 100 mg TID, AP306 125 mg TID, Placebo
Drug
Lead sponsor
R1 Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
24
States / cities
Huntsville, Alabama • Chula Vista, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 15, 2026, 4:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Pharmacokinetics of Oral EC5026 in Healthy Subjects

NCT04228302
View directory record Official record
Conditions
Healthy Adults
Interventions
EC5026 oral capsule, Placebo oral capsule
Drug · Other
Lead sponsor
EicOsis Human Health Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2021 · Synced Oct 15, 2026, 4:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Immunization Via Mosquito Bite With Radiation-attenuated Sporozoites

NCT01994525
View directory record Official record
Conditions
Malaria
Interventions
PfRAS, Placebo, Challenge
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 15, 2026, 4:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY3410738 in Healthy Adult Participants

NCT06181045
View directory record Official record
Conditions
Healthy
Interventions
LY3410738, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
Daytona Beach, Florida • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Oct 15, 2026, 4:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A First-in-human Study of Single Doses of PF-07328948 Which is Given to Healthy Adult Participants

NCT05654181
View directory record Official record
Conditions
Healthy
Interventions
PF-07328948, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Oct 15, 2026, 4:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of YJ001 in Healthy Volunteers

NCT05451667
View directory record Official record
Conditions
Safety and Tolerability
Interventions
YJ001 for Spray Use, Placebo of YJ001 for Spray Use
Drug
Lead sponsor
Yuejia Pharmaceuticals (USA), Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 15, 2026, 4:24 AM EDT
Completed Phase 2 Interventional Results available

Multi Immunotherapy to Test Tolerance and Xolair

NCT02626611
View directory record Official record
Conditions
Food Allergy
Interventions
Omalizumab, Food Flour Buildup
Drug
Lead sponsor
Kari Christine Nadeau
Other
Eligibility
4 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
7
States / cities
Los Angeles, California • Mountain View, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2017 · Synced Oct 15, 2026, 4:24 AM EDT
Completed Phase 3 Interventional Results available

Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)

NCT00256854
View directory record Official record
Conditions
Restless Legs Syndrome, Restless Legs Syndrome (RLS)
Interventions
Ropinirole IR 1 mg, Ropinirole IR 2 mg, Ropinirole IR 1 mg Placebo, Ropinirole IR 2 mg Placebo, Ropinirole CR 2 mg, Ropinirole CR 3 mg, Ropinirole CR 2 mg Placebo, Ropinirole CR 3 mg Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
30
States / cities
Laguna Hills, California • Oxnard, California • Pasadena, California + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2019 · Synced Oct 15, 2026, 4:24 AM EDT
Terminated Phase 1 Interventional

A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With Respiratory Syncytial Virus (RSV) Infection

NCT02593851
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections, Virus Diseases
Interventions
JNJ-53718678, Placebo
Drug
Lead sponsor
Janssen Sciences Ireland UC
Industry
Eligibility
1 Month to 24 Months
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Kirksville, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 6, 2019 · Synced Oct 15, 2026, 4:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1A Safety Trial of Inhaled PK10571 (GB002)

NCT03473236
View directory record Official record
Conditions
Safety Issues
Interventions
GB002, Generic Dry Powder Inhaler, Placebo
Drug · Device
Lead sponsor
GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2020 · Synced Oct 15, 2026, 4:24 AM EDT